InflaRx N.V. counts numerous specialized biotechnology venture capital firms, European institutional investors, and global asset management funds among its primary shareholders. Because it is a clinical-stage biopharmaceutical enterprise traded on Nasdaq, its equity distribution includes specialized healthcare funds, institutional funds filing public disclosures with regulatory bodies, and corporate insiders who originally backed its foundational scientific research into anti-inflammatory complement system therapeutics.